2025年12月21日，东方生物(688298)举办成立20周年庆典。庆典仪式上，公司董事长方剑秋发表致辞， 回顾企业从浙江安吉初创到跻身全球体外诊断领域重要参与者的发展历程，向长期支持企业的合作伙 伴、科研机构及全体员工致以感谢，并围绕技术创新、市场布局与未来战略展开展望，明确了这家中国 生物医疗企业的全球化发展方向。 从零起步：扎根安吉的创业初心 2005年，东方生物在浙江安吉正式成立。安吉不仅有着得天独厚的自然环境，更有着高效的营商环境， 为这家初创企业孕育了逐梦的沃土。"我们怀揣着对生物医疗事业的执着，开启了东方生物的创业征 程，并在接下来的二十年里，逐步走向国际舞台。"方剑秋在致辞中回忆道。 20年发展历程中，全球化始终是东方生物的重要战略方向。截至2025年，公司已在全球设立50余家分子 公司，组建起近3000人的团队，其中国内员工2800余人，海外员工190余人，形成一支融合多元文化、 可服务全球客户的国际化队伍。 在生产与供应链布局上，东方生物构建了"海内外协同"的体系。国内层面，除安吉、杭州两大总部基地 外，公司在上海、南京、成都、海南等地布局生命健康产业园及医学技术转化中心，依托完整产业链 ...

Core Viewpoint - FS Medical Supplies, LLC has filed a lawsuit against Zhejiang Oriental Gene Biological Products Co., Ltd. and its subsidiary, claiming breach of contract regarding a "no circumvention" clause related to COVID-19 testing kits [2][4]. Group 1: Lawsuit Details - The lawsuit was filed in the U.S. District Court for the Southern District of Texas, with the case number 4:25-CV-1332, and the cause of action is a contract dispute [4][6]. - The plaintiff alleges that the defendants violated the "no circumvention" clause by directly providing COVID-19 testing kits to FS Medical Supplies' customers, resulting in economic losses for the plaintiff [4][5]. - The plaintiff is seeking damages that include a penalty of no less than $1 billion, along with compensatory damages of at least $250 million, and other legal costs [6][7]. Group 2: Company Response and Impact - The company has engaged U.S. legal counsel to analyze the lawsuit's validity and intends to actively respond to the claims, asserting that the plaintiff's breach of contract claims are unfounded [7]. - The company has also initiated legal action against FS Medical Supplies in China, claiming that the framework agreement is invalid due to the plaintiff's lack of medical device operating licenses and false representations [7]. - Currently, the company's operations remain normal, and there are no frozen or restricted assets, indicating that the lawsuit will not impact the company's financial results for 2024, although future impacts remain uncertain [2][7].

Group 1: Company Strategy and Product Focus - The company positions itself as a leading enterprise in personal health management with a rich product line, focusing on core product development while exploring emerging product areas, including AI applications in health management [2] - In 2023, the company implemented a product focus strategy to enhance the competitiveness and brand influence of its core products, aiming for steady growth in sales scale and market share [2] Group 2: Product Structure and Market Dynamics - The diverse product structure provides strong risk resistance, allowing the company to maintain competitive capabilities despite fluctuations in product sales, such as the rise and fall of products like thermometers and masks [2] - The company has made strategic adjustments in 2024 to focus on core product development across supply chain, R&D, production, and distribution [2] Group 3: Financial Performance and Profitability - The company's gross margin has steadily increased due to product structure optimization, product upgrades, and expanded self-production capabilities [4] - The establishment of production bases has enabled the company to achieve self-research and production of core products, enhancing product performance and reducing production costs [4] Group 4: Hearing Aid Market Potential - The hearing aid market in China has significant growth potential, with a current penetration rate of less than 5%, compared to over 30% in developed countries [5] - The elderly population with hearing loss in China has reached 120 million, with a high incidence of moderate to severe hearing loss among those aged 65 and above [5] - The government has initiated actions to promote early screening and intervention for hearing loss, creating favorable conditions for industry growth [5] Group 5: M&A Plans - The company is actively looking for merger and acquisition opportunities within the industry that align with its strategic direction and can enhance its competitive advantage in niche markets [6]